Featured Research

from universities, journals, and other organizations

Soothing cells, peaceful protein could hold promise for treating autoimmune uveitis

Date:
June 30, 2014
Source:
NIH, National Eye Institute (NEI)
Summary:
Uveitis occurs when immune cells invade the eye, causing inflammation, swelling and vision loss. Researchers have found a unique type of immune cell and a secreted protein that, in tests on mice, can protect against the disease. Corticosteroids and other drugs that have a general suppressing effect on the immune system are typically the first-line treatments for uveitis. But over time, these drugs can cause a number of side effects, including weight gain, stomach ulcers, diabetes, heart disease, cataract and glaucoma.

Researchers at the National Eye Institute (NEI) have found a unique cell type that, in tests on mice, can protect against uveitis -- a group of inflammatory diseases that affect the eye and can cause vision loss.

Uveitis occurs when immune cells invade the eye, causing inflammation and swelling. The NEI researchers found a unique immune cell population that suppresses eye inflammation and reduces the severity of uveitis by releasing a protein called interleukin-35 (IL-35). The discovery, published in Nature Medicine, could lead to the development of new drugs based on IL-35 and to cellular therapies for uveitis.

Corticosteroids and other drugs that have a general suppressing effect on the immune system are typically the first-line treatments for uveitis. But over time, these drugs can cause a number of side effects, including weight gain, stomach ulcers, diabetes, heart disease, cataract and glaucoma. Biologics, which are drugs that are designed to target specific biological processes in the body, are another option. But currently available biologics were developed for a variety of diseases other than uveitis, and relatively little is known about the long-term benefits and risks of using them against uveitis.

"Usually, physicians use steroids and other current treatments sparingly, in order to avoid complications," said Charles Egwuagu, Ph.D., M.P.H., who is chief of the Molecular Immunology section in NEI's Laboratory of Immunology. "There has been a big push to develop biologics that would be more specific and effective for uveitis."

Uveitis literally means inflammation of the uvea, which is a middle layer of the eye that includes the iris (the colored ring) and the choroid, a tissue filled with tiny blood vessels. Normally, blood flow within these vessels is tightly regulated, creating a barrier between the bloodstream and the delicate tissues of the eye. But in uveitis, immune cells in the blood creep out of the vessels and wreak havoc in the eye. They can damage not only the uvea, but also the retina and the optic nerve. (The retina is the light-sensitive tissue at the back of the eye, and the optic nerve connects the retina to the brain.)

Uveitis can be triggered by eye infections or by autoimmunity, a process in which an overly aggressive response by the immune system results in damage to the body's own tissues. Autoimmune uveitis may occur as part of other autoimmune diseases such as juvenile rheumatoid arthritis, multiple sclerosis, Behçet's disease, and systemic lupus erythematosus. It is estimated that autoimmune uveitis accounts for 10 percent of all visual disabilities in the United States.

Dr. Egwuagu and his team have been working to understand autoimmune uveitis and other such disorders by studying complex feedback loops that are built into the immune response and normally keep it from turning against the body. Among immune cells, T cells generally serve as mobile infantry units, attacking invaders at close range. Meanwhile, B cells serve as the artillery units, attacking with guided missiles known as antibodies. In smaller numbers, there are also regulatory T cells and B cells that act as peacemakers, quieting down their armed, hostile counterparts. In recent years, there has been growing interest in harnessing these regulatory immune cells to calm down autoimmune responses.

There has been particular interest in IL-35, a member of a family of proteins called cytokines, which help tune immune responses. IL-35 was first discovered in 2007. It is produced by regulatory T cells and acts as a "calm down" signal for other cells. It is actually a pair of separate smaller proteins intimately joined together, and has proven difficult to purify or manufacture. Dr. Egwuagu's group is one of only two labs in the country that have been able to produce and study the complete protein, without using extra bits of protein called linkers to connect its two parts.

The researchers tested whether or not IL-35 could suppress autoimmune uveitis in a mouse model. To induce autoimmune uveitis in mice, they gave the mice injections of a retinal protein that appears to agitate immune cells in people with the condition. These mice developed damage to the uvea, retina, and optic nerve. But IL-35 injections given on the same day of disease induction helped prevent uveitis. When given up to 10 days after disease induction, IL-35 suppressed uveitis.

In other experiments done on laboratory-grown mouse cells, the researchers found that IL-35 protects against uveitis by changing the destiny of primitive B cells. Without IL-35, those cells typically become antibody-producing B cells. But IL-35 turns a fraction of those cells into regulatory B cells that produce more IL-35, creating a chain reaction of calm. The researchers found that IL-35 has the same effect on human B cells grown in the lab, suggesting it could have similar therapeutic effects in people as in mice. Finally, the researchers found that they could reverse uveitis in mice with injections of the regulatory B cells that produce IL-35, instead of injecting the protein itself. Ultimately, using the cells as therapy may be better than using the protein, Dr. Egwuagu said.

"We suspect that IL-35 is likely to have unpredictable side effects," he said. But the B cells responsible for producing it may produce other substances that balance these effects. "If you can grow and select for these cells, you can probably calibrate the effects of IL-35," he said.

Much work remains to be done to see if people with autoimmune uveitis could benefit from IL-35 or the cells that produce it. Testing in other animal models and methods for ramping up production of IL-35 will be necessary. Dr. Egwuagu also plans to investigate whether some people with autoimmune uveitis have a reduction or defect in regulatory B cells. If so, they would likely benefit from treatment with IL-35 or the regulatory B cells that produce it, said Dr. Egwuagu. There is also interest among the broader research community in determining if these therapies might be useful against other autoimmune diseases or organ transplant rejection.


Story Source:

The above story is based on materials provided by NIH, National Eye Institute (NEI). Note: Materials may be edited for content and length.


Journal Reference:

  1. Ren-Xi Wang, Cheng-Rong Yu, Ivy M Dambuza, Rashid M Mahdi, Monika B Dolinska, Yuri V Sergeev, Paul T Wingfield, Sung-Hye Kim, Charles E Egwuagu. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nature Medicine, 2014; 20 (6): 633 DOI: 10.1038/nm.3554

Cite This Page:

NIH, National Eye Institute (NEI). "Soothing cells, peaceful protein could hold promise for treating autoimmune uveitis." ScienceDaily. ScienceDaily, 30 June 2014. <www.sciencedaily.com/releases/2014/06/140630124252.htm>.
NIH, National Eye Institute (NEI). (2014, June 30). Soothing cells, peaceful protein could hold promise for treating autoimmune uveitis. ScienceDaily. Retrieved October 2, 2014 from www.sciencedaily.com/releases/2014/06/140630124252.htm
NIH, National Eye Institute (NEI). "Soothing cells, peaceful protein could hold promise for treating autoimmune uveitis." ScienceDaily. www.sciencedaily.com/releases/2014/06/140630124252.htm (accessed October 2, 2014).

Share This



More Health & Medicine News

Thursday, October 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pregnancy Spacing Could Have Big Impact On Autism Risks

Pregnancy Spacing Could Have Big Impact On Autism Risks

Newsy (Oct. 1, 2014) — A new study says children born less than one year and more than five years after a sibling can have an increased risk for autism. Video provided by Newsy
Powered by NewsLook.com
Robotic Hair Restoration

Robotic Hair Restoration

Ivanhoe (Oct. 1, 2014) — A new robotic procedure is changing the way we transplant hair. The ARTAS robot leaves no linear scarring and provides more natural results. Video provided by Ivanhoe
Powered by NewsLook.com
Insertable Cardiac Monitor

Insertable Cardiac Monitor

Ivanhoe (Oct. 1, 2014) — A heart monitor the size of a paperclip that can save your life. The “Reveal Linq” allows a doctor to monitor patients with A-Fib on a continuous basis for up to 3 years! Video provided by Ivanhoe
Powered by NewsLook.com
Attacking Superbugs

Attacking Superbugs

Ivanhoe (Oct. 1, 2014) — Two weapons hospitals can use to attack superbugs. Scientists in Ireland created a new gel resistant to superbugs, and a robot that can disinfect a room in minutes. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins